Document Detail

Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers.
MedLine Citation:
PMID:  20528630     Owner:  NLM     Status:  MEDLINE    
Microalbuminuria is an issue of great concern in hypertensive patients owing to its close relation with cardiovascular morbidity and mortality. Treatment should aim to reduce microalbuminuria to the normal range. Drugs that block the renin-angiotensin system have specific antiproteinuric properties, but more than one drug is needed to achieve blood pressure control in most cases. The aim of this study was to compare the effects of adding manidipine to the treatment of patients with essential hypertension and persistent albuminuria, despite full-dose treatment with a renin-angiotensin system blocker on urinary albumin excretion (UAE) after 24 weeks of therapy. Patients with diabetes and renal insufficiency were excluded. At baseline, blood pressure and UAE were 155.1 +/- 12/87.76 +/- 11 mmHg and 293.19 +/- 285 mg/g, respectively. At study end, blood pressure was 137.1 +/- 13.1/77.24 +/- 10.4 mmHg (p < 0.001 vs baseline). UAE was reduced by 45% to 161.52 +/- 163 mg/g (p < 0.001 vs baseline). No correlations were found between systolic blood pressure reduction and UAE reduction (Pearson's R = -0.034; p = not significant) nor between estimated glomerular filtration rate and UAE reduction (Pearson's R = -0.0056; p = not significant). No patient withdrew from the study owing to side effects. In conclusion, treatment with manidipine resulted in a large reduction in UAE rates, and this reduction appeared to be independent of the degree of blood pressure reduction or changes in estimated glomerular filtration rate. Our data supports the added value of manidipine in the treatment of patients with hypertension and microalbuminuria.
Josep Galceran; Jaume Plana; Angela Felip; Gabriel Pou; Joaquim Vila; Javier Sobrino
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of cardiovascular therapy     Volume:  8     ISSN:  1744-8344     ISO Abbreviation:  Expert Rev Cardiovasc Ther     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-09     Completed Date:  2010-10-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101182328     Medline TA:  Expert Rev Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  751-7     Citation Subset:  IM    
Nephrology Department, Althaia Foundation, Flor de Lis 33, 08242 Manresa, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Albuminuria / complications,  drug therapy*
Antihypertensive Agents / administration & dosage,  adverse effects,  therapeutic use*
Blood Pressure / drug effects
Calcium Channel Blockers / administration & dosage,  adverse effects,  therapeutic use*
Clinical Trials as Topic
Dihydropyridines / administration & dosage,  adverse effects,  therapeutic use*
Drug Therapy, Combination
Glomerular Filtration Rate / drug effects
Hypertension / complications,  drug therapy*,  physiopathology*
Middle Aged
Renin-Angiotensin System / drug effects*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Dihydropyridines; 89226-50-6/manidipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  News in brief.
Next Document:  Pregnancy and cardiovascular disease.